ADC Therapeutics Ltd ((ADCT)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
ADC Therapeutics Ltd is conducting a Phase 1b study titled ‘A Phase 1b Open-Label Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)’. The study aims to determine the optimal dosing regimen for loncastuximab tesirine in patients with specific types of lymphoma who also have liver impairment, which is crucial for tailoring treatments to this subgroup.
The intervention being tested is Loncastuximab Tesirine, an intravenous drug designed to treat diffuse large B-cell lymphoma and high-grade B-cell lymphoma. The study explores its pharmacokinetics and safety in patients with varying degrees of liver impairment.
The study is interventional with a non-randomized, parallel assignment model. It is open-label, meaning no masking is involved, and its primary purpose is basic science, focusing on understanding the drug’s behavior in the body.
The study began on December 13, 2022, with the latest update submitted on July 14, 2025. These dates are important as they indicate the study’s progress and the timeliness of the data being collected.
This update could influence ADC Therapeutics’ stock performance positively by showcasing their commitment to expanding treatment options for complex patient populations. The study’s progress might also affect investor sentiment, as successful results could enhance the company’s competitive edge in the oncology market.
The study is ongoing, with further details available on the ClinicalTrials portal.